| pubmed-article:18582999 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18582999 | lifeskim:mentions | umls-concept:C0220847 | lld:lifeskim |
| pubmed-article:18582999 | lifeskim:mentions | umls-concept:C1332717 | lld:lifeskim |
| pubmed-article:18582999 | lifeskim:mentions | umls-concept:C1706438 | lld:lifeskim |
| pubmed-article:18582999 | lifeskim:mentions | umls-concept:C0085358 | lld:lifeskim |
| pubmed-article:18582999 | lifeskim:mentions | umls-concept:C0282580 | lld:lifeskim |
| pubmed-article:18582999 | lifeskim:mentions | umls-concept:C1413244 | lld:lifeskim |
| pubmed-article:18582999 | lifeskim:mentions | umls-concept:C2698600 | lld:lifeskim |
| pubmed-article:18582999 | pubmed:issue | 31 | lld:pubmed |
| pubmed-article:18582999 | pubmed:dateCreated | 2008-7-8 | lld:pubmed |
| pubmed-article:18582999 | pubmed:abstractText | The HCV-specific HLA-A2-restricted NS3(1073) epitope is one of the most frequently recognized epitopes in hepatitis C. NS3(1073)-specific T-cell responses are associated with clearance of acute HCV-infection. Therefore this epitope is an interesting candidate for a HCV-peptide vaccine. However, heterogeneity between genotypes and mutations in the epitope has to be considered as an obstacle. We here identified 34 naturally occurring NS3(1073)-variants, as compared with the wild type genotype-1 variants (CVNGVCWTV/CINGVCWTV) by sequencing sera of 251 Greek and German patients and searching for published HCV-genomes. The frequency of variants among genotype-1 patients was 10%. Importantly, HLA-A2 binding was reduced only in 3 genotype 1 mutants while all non-genotype 1 variants showed strong HLA-A2-binding. By screening 28 variants in ELISPOT assays from T cell lines we could demonstrate that HCV-NS3(1073)-wild-type-specific T-cells displayed cross-genotype-reactivity, in particular against genotypes 4-6 variants. However, single aa changes within the TCR-binding domain completely abolished recognition even in case of conservative aa exchanges within genotype-1. NS3(1073)-specific T-cell lines from recovered, chronically infected, and HCV-negative individuals showed no major difference in the pattern of cross-recognition although the proliferation of NS3(1073)-specific T-cells differed significantly between the groups. Importantly, the recognition pattern against the 28 variants was also identical directly ex vivo in a patient with acute HCV infection and a healthy volunteer vaccinated with the peptide vaccine IC41 containing the NS3(1073)-wild-type peptide. Thus, partial cross-genotype recognition of HCV NS3(1073)-specific CD8 T cells is possible; however, even single aa exchanges can significantly limit the potential efficacy of vaccines containing the NS3(1073)-wild-type peptide. | lld:pubmed |
| pubmed-article:18582999 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18582999 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18582999 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18582999 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18582999 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18582999 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18582999 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18582999 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18582999 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18582999 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:18582999 | pubmed:issn | 0264-410X | lld:pubmed |
| pubmed-article:18582999 | pubmed:author | pubmed-author:BergTT | lld:pubmed |
| pubmed-article:18582999 | pubmed:author | pubmed-author:MannoM LML | lld:pubmed |
| pubmed-article:18582999 | pubmed:author | pubmed-author:SarrazinCC | lld:pubmed |
| pubmed-article:18582999 | pubmed:author | pubmed-author:ZaunerWW | lld:pubmed |
| pubmed-article:18582999 | pubmed:author | pubmed-author:DalekosG NGN | lld:pubmed |
| pubmed-article:18582999 | pubmed:author | pubmed-author:WedemeyerHH | lld:pubmed |
| pubmed-article:18582999 | pubmed:author | pubmed-author:CornbergMM | lld:pubmed |
| pubmed-article:18582999 | pubmed:author | pubmed-author:ZachouKK | lld:pubmed |
| pubmed-article:18582999 | pubmed:author | pubmed-author:KladeC SCS | lld:pubmed |
| pubmed-article:18582999 | pubmed:author | pubmed-author:SuneethaP VPV | lld:pubmed |
| pubmed-article:18582999 | pubmed:author | pubmed-author:FytiliPP | lld:pubmed |
| pubmed-article:18582999 | pubmed:author | pubmed-author:SchlaphoffVV | lld:pubmed |
| pubmed-article:18582999 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18582999 | pubmed:day | 23 | lld:pubmed |
| pubmed-article:18582999 | pubmed:volume | 26 | lld:pubmed |
| pubmed-article:18582999 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18582999 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18582999 | pubmed:pagination | 3818-26 | lld:pubmed |
| pubmed-article:18582999 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:18582999 | pubmed:meshHeading | pubmed-meshheading:18582999... | lld:pubmed |
| pubmed-article:18582999 | pubmed:meshHeading | pubmed-meshheading:18582999... | lld:pubmed |
| pubmed-article:18582999 | pubmed:meshHeading | pubmed-meshheading:18582999... | lld:pubmed |
| pubmed-article:18582999 | pubmed:meshHeading | pubmed-meshheading:18582999... | lld:pubmed |
| pubmed-article:18582999 | pubmed:meshHeading | pubmed-meshheading:18582999... | lld:pubmed |
| pubmed-article:18582999 | pubmed:meshHeading | pubmed-meshheading:18582999... | lld:pubmed |
| pubmed-article:18582999 | pubmed:meshHeading | pubmed-meshheading:18582999... | lld:pubmed |
| pubmed-article:18582999 | pubmed:meshHeading | pubmed-meshheading:18582999... | lld:pubmed |
| pubmed-article:18582999 | pubmed:meshHeading | pubmed-meshheading:18582999... | lld:pubmed |
| pubmed-article:18582999 | pubmed:meshHeading | pubmed-meshheading:18582999... | lld:pubmed |
| pubmed-article:18582999 | pubmed:meshHeading | pubmed-meshheading:18582999... | lld:pubmed |
| pubmed-article:18582999 | pubmed:meshHeading | pubmed-meshheading:18582999... | lld:pubmed |
| pubmed-article:18582999 | pubmed:meshHeading | pubmed-meshheading:18582999... | lld:pubmed |
| pubmed-article:18582999 | pubmed:meshHeading | pubmed-meshheading:18582999... | lld:pubmed |
| pubmed-article:18582999 | pubmed:meshHeading | pubmed-meshheading:18582999... | lld:pubmed |
| pubmed-article:18582999 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18582999 | pubmed:articleTitle | Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073. | lld:pubmed |
| pubmed-article:18582999 | pubmed:affiliation | Medizinische Hochschule Hannover, Abt. Gastroenterologie, Hepatologie und Endokrinologie, Carl-Neuberg Strasse 1, 30625 Hannover, Germany. | lld:pubmed |
| pubmed-article:18582999 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18582999 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18582999 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18582999 | lld:pubmed |
